




# MEDICINAL PRODUCTS 2022



MyMD Pharmaceuticals Inc.  
Rank 44 of 51





RealRate

# MEDICINAL PRODUCTS 2022

## MyMD Pharmaceuticals Inc. Rank 44 of 51



The relative strengths and weaknesses of MyMD Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyMD Pharmaceuticals Inc. compared to the market average is the variable Assets, Non-Current, increasing the Economic Capital Ratio by 136% points. The greatest weakness of MyMD Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 178% points.

The company's Economic Capital Ratio, given in the ranking table, is -75%, being 62% points below the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	12,665
Assets, Non-Current	12,148
General and Administrative Expense	6,420
Goodwill	10,499
Liabilities, Current	1,040
Liabilities, Non-Current	126
Other Assets	-10,499
Other Compr. Net Income	0
Other Expenses	15,645
Other Liabilities	0
Other Net Income	-1,079
Other Revenues	0
Property, Plant and Equipment, Net	0
Research and Development	6,745

Output Variable	Value in 1000 USD
Liabilities	1,166
Assets	24,813
Expenses	28,810
Revenues	0
Stockholders Equity	23,647
Net Income	-29,889
Comprehensive Net Income	-29,889
Economic Capital Ratio	-75%